{"id":25462,"date":"2022-09-23T00:18:00","date_gmt":"2022-09-22T16:18:00","guid":{"rendered":"https:\/\/flcube.com\/?p=25462"},"modified":"2025-02-05T00:21:51","modified_gmt":"2025-02-04T16:21:51","slug":"jenscare-scientific-set-for-ipo-to-fund-structural-heart-disease-solutions","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=25462","title":{"rendered":"Jenscare Scientific Set for IPO to Fund Structural Heart Disease Solutions"},"content":{"rendered":"\n<p>Jenscare Scientific Co., Ltd., a structural heart disease intervention device maker based in Ningbo, is set to make an initial public offering (IPO) of 8.08 million shares on the Hong Kong Stock Exchange. The IPO is priced at HKD 28.8 ($3.67) per share, raising a total of HKD 232.6 million.<\/p>\n\n\n\n<p><strong>Company Overview and Core Products<\/strong><br>Founded in 2011, Jenscare provides a range of treatment solutions for different types of structural heart disease, including tricuspid valve disease, aortic valve disease, mitral valve disease, and heart failure. The company\u2019s core product, LuX-Valve, is a first-generation transcatheter tricuspid valve replacement (TTR) system designed for patients with severe tricuspid regurgitation and high surgical risk. Another core product, Ken-Valve, is designed for the treatment of severe aortic valve regurgitation (or combined aortic valve stenosis), addressing patient needs beyond those of transcatheter aortic valve replacement solely for the treatment of aortic valve stenosis.<\/p>\n\n\n\n<p><strong>Use of Proceeds<\/strong><br>The proceeds from the IPO will be used to fund R&amp;D, manufacturing, and commercialization of core products LuX-Valve and Ken-Valve. This includes continuing R&amp;D, clinical studies, regulatory filings, and commercialization efforts for these products, as well as R&amp;D, clinical studies, and regulatory filings for other product pipelines. The funds will also support working capital.<\/p>\n\n\n\n<p><strong>Financial Performance<\/strong><br>Jenscare recorded a net loss of RMB 500.7 million ($70.5 million) in 2021 and RMB 73.5 million ($10.3 million) in the first six months of 2022, primarily due to R&amp;D and administrative expenses. Despite the losses, the company\u2019s net assets surged to RMB 1.29 billion ($181.6 million) in 2021 from RMB 352.8 million ($49.6 million) in 2020.<\/p>\n\n\n\n<p><strong>Future Outlook<\/strong><br>The IPO marks a significant step for Jenscare as it seeks to expand its capabilities in structural heart disease intervention. With the funds raised, the company is well-positioned to advance its core products and pipeline, ultimately contributing to improved treatment options for patients with complex heart conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Jenscare Scientific Co., Ltd., a structural heart disease intervention device maker based in Ningbo, is&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[72,583],"class_list":["post-25462","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-ipo","tag-jenscare-scientific"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Jenscare Scientific Set for IPO to Fund Structural Heart Disease Solutions - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jenscare Scientific Co., Ltd., a structural heart disease intervention device maker based in Ningbo, is set to make an initial public offering (IPO) of 8.08 million shares on the Hong Kong Stock Exchange. The IPO is priced at HKD 28.8 ($3.67) per share, raising a total of HKD 232.6 million.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=25462\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jenscare Scientific Set for IPO to Fund Structural Heart Disease Solutions\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=25462\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-22T16:18:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-04T16:21:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25462#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25462\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jenscare Scientific Set for IPO to Fund Structural Heart Disease Solutions\",\"datePublished\":\"2022-09-22T16:18:00+00:00\",\"dateModified\":\"2025-02-04T16:21:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25462\"},\"wordCount\":320,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"IPO\",\"Jenscare Scientific\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25462#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25462\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=25462\",\"name\":\"Jenscare Scientific Set for IPO to Fund Structural Heart Disease Solutions - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-09-22T16:18:00+00:00\",\"dateModified\":\"2025-02-04T16:21:51+00:00\",\"description\":\"Jenscare Scientific Co., Ltd., a structural heart disease intervention device maker based in Ningbo, is set to make an initial public offering (IPO) of 8.08 million shares on the Hong Kong Stock Exchange. The IPO is priced at HKD 28.8 ($3.67) per share, raising a total of HKD 232.6 million.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25462#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25462\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25462#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jenscare Scientific Set for IPO to Fund Structural Heart Disease Solutions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jenscare Scientific Set for IPO to Fund Structural Heart Disease Solutions - Insight, China&#039;s Pharmaceutical Industry","description":"Jenscare Scientific Co., Ltd., a structural heart disease intervention device maker based in Ningbo, is set to make an initial public offering (IPO) of 8.08 million shares on the Hong Kong Stock Exchange. The IPO is priced at HKD 28.8 ($3.67) per share, raising a total of HKD 232.6 million.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=25462","og_locale":"en_US","og_type":"article","og_title":"Jenscare Scientific Set for IPO to Fund Structural Heart Disease Solutions","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=25462","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-09-22T16:18:00+00:00","article_modified_time":"2025-02-04T16:21:51+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=25462#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=25462"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jenscare Scientific Set for IPO to Fund Structural Heart Disease Solutions","datePublished":"2022-09-22T16:18:00+00:00","dateModified":"2025-02-04T16:21:51+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=25462"},"wordCount":320,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["IPO","Jenscare Scientific"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=25462#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=25462","url":"https:\/\/flcube.com\/?p=25462","name":"Jenscare Scientific Set for IPO to Fund Structural Heart Disease Solutions - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-09-22T16:18:00+00:00","dateModified":"2025-02-04T16:21:51+00:00","description":"Jenscare Scientific Co., Ltd., a structural heart disease intervention device maker based in Ningbo, is set to make an initial public offering (IPO) of 8.08 million shares on the Hong Kong Stock Exchange. The IPO is priced at HKD 28.8 ($3.67) per share, raising a total of HKD 232.6 million.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=25462#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=25462"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=25462#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jenscare Scientific Set for IPO to Fund Structural Heart Disease Solutions"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25462","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25462"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25462\/revisions"}],"predecessor-version":[{"id":25463,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25462\/revisions\/25463"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25462"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=25462"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=25462"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}